Compare SY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | VYGR |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7M | 203.6M |
| IPO Year | 2018 | 2015 |
| Metric | SY | VYGR |
|---|---|---|
| Price | $2.16 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $16.50 |
| AVG Volume (30 Days) | 205.3K | ★ 617.9K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $38.64 | $34.04 |
| Revenue Next Year | $30.63 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $2.94 |
| 52 Week High | $5.35 | $5.55 |
| Indicator | SY | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 45.16 |
| Support Level | $1.68 | $2.96 |
| Resistance Level | $2.15 | $3.28 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 80.46 | 56.52 |
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.